• Rebecca T Hahn, Philippe Pibarot, William J Stewart, Neil J Weissman, Deepika Gopalakrishnan, Martin G Keane, Saif Anwaruddin, Zuyue Wang, Martin Bilsker, Brian R Lindman, Howard C Herrmann, Susheel K Kodali, Raj Makkar, Vinod H Thourani, Lars G Svensson, Jodi J Akin, William N Anderson, Martin B Leon, and Pamela S Douglas.
• NYP Columbia Heart Valve Center, Columbia University Medical Center, New York, New York 10032, USA. rth2@columbia.edu
• J. Am. Coll. Cardiol. 2013 Jun 25;61(25):2514-21.

ObjectivesThis study sought to compare echocardiographic findings in patients with critical aortic stenosis following surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR).BackgroundThe PARTNER (Placement of Aortic Transcatheter Valves) trial randomized patients 1:1 to SAVR or TAVR.MethodsEchocardiograms were obtained at baseline, discharge, 30 days, 6 months, 1 year, and 2 years after the procedure and analyzed in a core laboratory. For the analysis of post-implantation variables, the first interpretable study (≤6 months) was used.ResultsBoth groups showed a decrease in aortic valve gradients and increase in effective orifice area (EOA) (p < 0.0001), which remained stable over 2 years. Compared with SAVR, TAVR resulted in larger indexed EOA (p = 0.038), less prosthesis-patient mismatch (p = 0.019), and more total and paravalvular aortic regurgitation (p < 0.0001). Baseline echocardiographic univariate predictors of death were lower peak transaortic gradient in TAVR patients, and low left ventricular diastolic volume, low stroke volume, and greater severity of mitral regurgitation in SAVR patients. Post-implantation echocardiographic univariate predictors of death were: larger left ventricular diastolic volume, left ventricular systolic volume and EOA, decreased ejection fraction, and greater aortic regurgitation in TAVR patients; and smaller left ventricular systolic and diastolic volumes, low stroke volume, smaller EOA, and prosthesis-patient mismatch in SAVR patients.ConclusionsPatients randomized to either SAVR or TAVR experience enduring, significant reductions in transaortic gradients and increase in EOA. Compared with SAVR, TAVR patients had higher indexed EOA, lower prosthesis-patient mismatch, and more aortic regurgitation. Univariate predictors of death for the TAVR and SAVR groups differed and might allow future refinement in patient selection. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial; NCT00530894).Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

20 keywords...

hide…